VIVUS (VVUS) Banks On New Drug Pancreaze, Qsymia Lacks Luster
Zacks Investment Research | Jan 03, 2019 03:29AM ET
On Jan 2, we issued an updated research report on VIVUS, Inc. (NASDAQ:VVUS) . The company's portfolio comprises three drugs, Qsymia for chronic weight management, Stendra for erectile dysfunction ("ED") and recently acquired Pancreaze for exocrine pancreatic insufficiency (“EPI”).
Shares of VIVUS have fallen 68.6% in the past six months compared with the industry ’s decline of 15.7%.
The company remains focused on maximizing the value of and monetizing its legacy products, Qsymia and Stendra. Qsymia sales were lackluster in 2018 due to challenges in the obesity market. Its uptake has been slow due to high out-of-pocket cost burden for patients as a result of lack of reimbursement for the product.
However, the company remains committed to reimbursement and promotional initiatives to boost sales of the drug. Moreover, settlement of patent litigations with Teva (NYSE:TEVA) and Dr. Reddy’s (NYSE:RDY) in 2017 has pushed back generic competition to late 2024.
Early last year, the company had announced its intentions to build a portfolio of commercial drugs with positive cash flow. In May 2018, the company acquired a cash-flow positive drug, Pancreaze, as part of the strategy from Johnson & Johnson (NYSE:JNJ) . The acquisition has been encouraging as the drug had a strong contribution to the company’s topline in three months ending September, its first full quarter after acquisition.
The company is also developing a proprietary soft capsule formulation of tacrolimus for the treatment of pulmonary arterial hypertension. However, its development is in early stages.
Zacks Rank
VIVUS currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Get The News You Want
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.